These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 23377183)

  • 1. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
    Meyer JA; Wang J; Hogan LE; Yang JJ; Dandekar S; Patel JP; Tang Z; Zumbo P; Li S; Zavadil J; Levine RL; Cardozo T; Hunger SP; Raetz EA; Evans WE; Morrison DJ; Mason CE; Carroll WL
    Nat Genet; 2013 Mar; 45(3):290-4. PubMed ID: 23377183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
    Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
    Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
    Barz MJ; Hof J; Groeneveld-Krentz S; Loh JW; Szymansky A; Astrahantseff K; von Stackelberg A; Khiabanian H; Ferrando AA; Eckert C; Kirschner-Schwabe R
    Blood; 2020 Mar; 135(12):921-933. PubMed ID: 31971569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9-Mediated Induction of Relapse-Specific
    Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
    Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
    Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
    Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
    Tzoneva G; Dieck CL; Oshima K; Ambesi-Impiombato A; Sánchez-Martín M; Madubata CJ; Khiabanian H; Yu J; Waanders E; Iacobucci I; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Kirschner-Schwabe R; Mullighan CG; Rabadan R; Ferrando AA
    Nature; 2018 Jan; 553(7689):511-514. PubMed ID: 29342136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?
    Meyer JA; Carroll WL; Bhatla T
    Expert Rev Hematol; 2013 Jun; 6(3):223-4. PubMed ID: 23782074
    [No Abstract]   [Full Text] [Related]  

  • 8. Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
    Hnízda A; Fábry M; Moriyama T; Pachl P; Kugler M; Brinsa V; Ascher DB; Carroll WL; Novák P; Žaliová M; Trka J; Řezáčová P; Yang JJ; Veverka V
    Leukemia; 2018 Jun; 32(6):1393-1403. PubMed ID: 29535428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia.
    Torres-Diz M; Reglero C; Falkenstein CD; Castro A; Hayer KE; Radens CM; Quesnel-Vallières M; Ang Z; Sehgal P; Li MM; Barash Y; Tasian SK; Ferrando A; Thomas-Tikhonenko A
    Cancer Res; 2024 Oct; 84(20):3327-3336. PubMed ID: 39094066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
    Dieck CL; Ferrando A
    Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
    Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
    Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of
    Moriyama T; Liu S; Li J; Meyer J; Zhao X; Yang W; Shao Y; Heath R; Hnízda A; Carroll WL; Yang JJ
    Mol Cancer Ther; 2019 Oct; 18(10):1887-1895. PubMed ID: 31358663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
    Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
    Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia.
    Reglero C; Dieck CL; Zask A; Forouhar F; Laurent AP; Lin WW; Albero R; Miller HI; Ma C; Gastier-Foster JM; Loh ML; Tong L; Stockwell BR; Palomero T; Ferrando AA
    Cancer Discov; 2022 Nov; 12(11):2646-2665. PubMed ID: 35984649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [NT5C2 expression in children with acute leukemia and its clinical significance].
    Wang Y; An X; Liu J; Zhang N; Liu Z; Liang S; Yu J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):748-53. PubMed ID: 26462774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligomeric interface modulation causes misregulation of purine 5´-nucleotidase in relapsed leukemia.
    Hnízda A; Škerlová J; Fábry M; Pachl P; Šinalová M; Vrzal L; Man P; Novák P; Řezáčová P; Veverka V
    BMC Biol; 2016 Oct; 14(1):91. PubMed ID: 27756303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
    Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
    J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant splicing in B-cell acute lymphoblastic leukemia.
    Black KL; Naqvi AS; Asnani M; Hayer KE; Yang SY; Gillespie E; Bagashev A; Pillai V; Tasian SK; Gazzara MR; Carroll M; Taylor D; Lynch KW; Barash Y; Thomas-Tikhonenko A
    Nucleic Acids Res; 2018 Nov; 46(21):11357-11369. PubMed ID: 30357359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
    Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
    J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia.
    Yu SL; Zhang H; Ho BC; Yu CH; Chang CC; Hsu YC; Ni YL; Lin KH; Jou ST; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Pui CH; Yang JJ; Zhang J; Lin DT; Lin SW; Ma X; Yang YL
    Sci Rep; 2020 Jul; 10(1):12074. PubMed ID: 32694622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.